查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1298441

胃癌市場：按疾病類型、治療類型、藥物類別展望、給藥途徑、分銷渠道：2021-2031年全球機會分析和行業預測

Gastric Cancer Market By Disease Type, By Treatment Type, By Drug Class Outlook, By Route of Administration, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 350 Pages | 商品交期: 2-3個工作天內

價格

全球胃癌市場預計將從2021年的21億美元增長到2031年的107億美元，2022年至2031年的複合年增長率為17.9%。

胃癌市場-IMG1

胃癌是一種在胃粘膜中形成惡性（癌）細胞的疾病。年齡、飲食和久坐的生活方式都會增加患胃癌的風險。胃癌的症狀包括消化不良和胃部不適或疼痛。檢查胃和食道的檢查用於診斷胃癌。

胃癌患者數量呈上升趨勢，胃癌市場有望擴大。隨著肥胖增加、高度加工食品、含糖飲料攝入量增加、吸煙、轉基因基因、癌症家族史和飲酒等其他危險因素的增加，導致胃癌的原因顯著增加。此外，胃癌的發病率預計將繼續上升，推動對有效治療的需求。所有這些因素預計將在預測期內推動市場收入增長。

由於必須進行許多檢查，包括手術、放射治療、診斷和分期，胃癌治療可能會很昂貴。胃癌的診斷和分期通常需要各種測試和程序，包括影像學研究、內窺鏡檢查、活檢和血液檢查。這些測試費用昂貴，並且可能需要多次就診。由於胃癌治療費用高昂，預計市場將受到嚴重限制。

預計胃癌市場將受益於醫療保健意識的提高。隨著對與胃癌相關的危險因素的認識不斷提高，人們更有可能尋求醫療救助並接受篩查。隨著人們對胃癌認識的提高，更多的病例將在早期被發現。胃癌的早期發現對於有效治療和改善患者預後至關重要。因此，胃癌患者可能需要藥物治療、手術和放射治療等診斷和治療選擇。預計這些因素將為市場上的主要參與者創造一些增長機會。

COVID-19大流行對胃癌的治療產生了不利影響，尤其是篩查、診斷和治療的時機。COVID-19是一場史無前例的全球突發公共衛生事件，幾乎影響到了每個行業，其長期影響將體現在疫情後各最終用途行業的增長中。由於大流行，許多胃癌患者的治療中斷。為了降低感染COVID-19的風險，治療方案不得不改變，導致一些患者的治療計劃被推遲或改變。由於擔心醫療機構中暴露於 COVID-19，患者對尋求治療猶豫不決。胃癌臨床試驗受到疫情的嚴重影響，許多臨床試驗被推遲或延遲。

目錄

第 1 章 簡介

第二章執行摘要

第三章市場概況

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資口袋
  • 波特五力分析
  • 市場動態
    • 促進者
    • 抑製劑
    • 機會
  • COVID-19：市場影響分析
  • 平均售價
  • 品牌佔有率分析
  • 關鍵監管分析
  • 市場份額分析
  • 專利情況
  • 監管指南
  • 價值鏈分析

4 胃癌市場：按疾病類型

  • 概述
    • 市場規模和預測
  • 腺癌
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 淋巴瘤
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 胃腸道間質瘤
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 類癌瘤
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 其他
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類

5 胃癌市場（按治療類型）

  • 概述
    • 市場規模和預測
  • 免疫療法
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 靶向治療
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 化學處理
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 放射治療/手術
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類

6. 胃癌市場：按藥物類別展望

  • 概述
    • 市場規模和預測
  • PD-1/PD-L1抑製劑
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家分類
  • H2拮抗劑
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • H2拮抗劑
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 其他
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類

7. 胃癌市場：按給藥途徑分類

  • 概述
    • 市場規模和預測
  • 口服
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 注射
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類

8. 胃癌市場：按分銷渠道劃分

  • 概述
    • 市場規模和預測
  • 醫院藥房
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 專業藥房和零售藥房
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 其他
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類

9.按地區劃分的胃癌市場

  • 概述
    • 市場規模/預測：按地區
  • 北美
    • 主要趨勢和機遇
    • 市場規模和預測：按疾病類型
    • 市場規模和預測：按治療類型
    • 市場規模和預測：按藥物類別展望
    • 市場規模和預測：按管理途徑
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家
      • 美國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按治療類型
      • 市場規模和預測：按藥物類別展望
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 加拿大
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按治療類型
      • 市場規模和預測：按藥物類別展望
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 墨西哥
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按治療類型
      • 市場規模和預測：按藥物類別展望
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
  • 歐洲
    • 主要趨勢和機遇
    • 市場規模和預測：按疾病類型
    • 市場規模和預測：按治療類型
    • 市場規模和預測：按藥物類別展望
    • 市場規模和預測：按管理途徑
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家
      • 德國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按治療類型
      • 市場規模和預測：按藥物類別展望
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 英國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按治療類型
      • 市場規模和預測：按藥物類別展望
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 法國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按治療類型
      • 市場規模和預測：按藥物類別展望
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 西班牙
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按治療類型
      • 市場規模和預測：按藥物類別展望
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 意大利
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按治療類型
      • 市場規模和預測：按藥物類別展望
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 歐洲其他地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按治療類型
      • 市場規模和預測：按藥物類別展望
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
  • 亞太地區
    • 主要趨勢和機遇
    • 市場規模和預測：按疾病類型
    • 市場規模和預測：按治療類型
    • 市場規模和預測：按藥物類別展望
    • 市場規模和預測：按管理途徑
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家
      • 中國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按治療類型
      • 市場規模和預測：按藥物類別展望
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 日本
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按治療類型
      • 市場規模和預測：按藥物類別展望
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 印度
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按治療類型
      • 市場規模和預測：按藥物類別展望
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 韓國市場
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按治療類型
      • 市場規模和預測：按藥物類別展望
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 澳大利亞
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按治療類型
      • 市場規模和預測：按藥物類別展望
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 亞太其他地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按治療類型
      • 市場規模和預測：按藥物類別展望
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
  • 拉丁美洲/中東/非洲
    • 主要趨勢和機遇
    • 市場規模和預測：按疾病類型
    • 市場規模和預測：按治療類型
    • 市場規模和預測：按藥物類別展望
    • 市場規模和預測：按管理途徑
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家
      • 巴西
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按治療類型
      • 市場規模和預測：按藥物類別展望
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 阿拉伯聯合酋長國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按治療類型
      • 市場規模和預測：按藥物類別展望
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 沙特阿拉伯
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按治療類型
      • 市場規模和預測：按藥物類別展望
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 南非
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按治療類型
      • 市場規模和預測：按藥物類別展望
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 其他地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按治療類型
      • 市場規模和預測：按藥物類別展望
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分

第10章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10大公司產品圖
  • 比賽儀表板
  • 比賽熱圖
  • 2021 年頂級公司定位

第十一章公司簡介

  • Novartis AG
  • Pfizer, Inc.
  • Mylan N.V.
  • F. Hoffmann La Roche Ltd.
  • Eli Lilly And Company
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Celltrion Healthcare Co., Ltd.
  • samsung bioepis
  • Bristol Myers Squibb Company
Product Code: A74458

The global gastric cancer market is anticipated to reach $10.7 billion by 2031, growing from $2.1 billion in 2021, at a CAGR of 17.9% from 2022 to 2031.

Gastric Cancer Market - IMG1

Gastric cancer is a disease in which malignant (cancer) cells form in the lining of the stomach. Age, diet, and sedentary lifestyle can lead to the risk of developing gastric cancer. Symptoms of gastric cancer include indigestion and stomach discomfort or pain. Tests that examine the stomach and esophagus are used to diagnose gastric cancer.

The gastric cancer market is expected to expand as cases of the stomach disease rise. The causes of stomach cancer have significantly increased due to additional risk factors such as an increase in obesity, increase in the consumption of highly processed foods, sugary beverages, smoking, genetic modification of genes, a family history of cancer, and consumption of alcohol. Furthermore, the rising incidence of gastric cancer is anticipated to continue and this trend is boosting the demand for efficient treatments. All these factors are projected to drive the market revenue growth during the forecast period.

Gastric cancer treatment can be expensive as there are numerous tests which need to be conducted, including surgery, radiation therapy, and diagnosis, and staging. Different tests and procedures, such as imaging studies, endoscopies, biopsies, and blood tests, are frequently required in the diagnosis and staging of gastric cancer. The cost of these tests can be high, and multiple doctor visits might be necessary. The market is predicted to be severely constrained by the high cost of treating gastric cancer.

The market for gastric cancer is projected to benefit due to the increase in healthcare awareness. People are more likely to seek medical attention and get screened for the disease as they become more aware of the risk factors linked to gastric cancer. More cases of gastric cancer can be discovered at an earlier stage owing to the increase in awareness. Early detection of gastric cancer is essential for effective treatment and better patient outcomes. Therefore, gastric cancer patient may need diagnostic and therapeutic options like medication, surgery, and radiation therapy. These factors are expected to create several growth opportunities for the major players operating in the market.

The COVID-19 pandemic had a detrimental effect on the treatment of gastric cancer, especially in terms of the timing of screening, diagnosis, and treatment.COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the post-pandemic period. Many gastric cancer patients have experienced treatment interruptions due to the pandemic. To reduce the risk of COVID-19 transmission, treatment schedules had to be altered, which resulted in delays or changes to some patients' treatment plans. Concerns about COVID-19 exposure in healthcare settings made patients hesitant to seek treatment. Clinical trials for gastric cancer were significantly impacted by the pandemic as numerous clinical trials were postponed or delayed.

The key players profiled in this report include: Novartis AG, Pfizer, Inc., Mylan N.V., F. Hoffmann La Roche Ltd., Eli Lilly and Company, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Celltrion Healthcare Co., Ltd., Samsung Bioepis and Bristol Myers Squibb Company

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the gastric cancer market analysis from 2021 to 2031 to identify the prevailing gastric cancer market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the gastric cancer market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global gastric cancer market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Disease Type

  • Adenocarcinoma
  • Lymphoma
  • Gastrointestinal Stromal Tumor
  • Carcinoid Tumor
  • Others

By Treatment Type

  • Immunotherapy
  • Targeted Therapy
  • Chemotherapy
  • Radiation Therapy and Surgery

By Drug Class Outlook

  • PD-1/PD-L1 Inhibitors
  • HER2 Antagonists
  • VEGFR2 Antagonists
  • Others

By Route of Administration

  • Oral
  • Injectable

By Distribution Channel

  • Specialty and Retail Pharmacies
  • Others
  • Hospital Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Novartis AG
    • Pfizer, Inc.
    • Mylan N.V.
    • F. Hoffmann La Roche Ltd.
    • Eli Lilly And Company
    • Merck & Co., Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Celltrion Healthcare Co., Ltd.
    • samsung bioepis
    • Bristol Myers Squibb Company

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
  • 3.4. Market dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities
  • 3.5. COVID-19 Impact Analysis on the market
  • 3.6. Average Selling Price
  • 3.7. Brand Share Analysis
  • 3.8. Key Regulation Analysis
  • 3.9. Market Share Analysis
  • 3.10. Patent Landscape
  • 3.11. Regulatory Guidelines
  • 3.12. Value Chain Analysis

CHAPTER 4: GASTRIC CANCER MARKET, BY DISEASE TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Adenocarcinoma
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Lymphoma
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Gastrointestinal Stromal Tumor
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Carcinoid Tumor
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country
  • 4.6. Others
    • 4.6.1. Key market trends, growth factors and opportunities
    • 4.6.2. Market size and forecast, by region
    • 4.6.3. Market share analysis by country

CHAPTER 5: GASTRIC CANCER MARKET, BY TREATMENT TYPE

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Immunotherapy
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Targeted Therapy
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Chemotherapy
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Radiation Therapy and Surgery
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country

CHAPTER 6: GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. PD-1/PD-L1 Inhibitors
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. HER2 Antagonists
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. VEGFR2 Antagonists
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country
  • 6.5. Others
    • 6.5.1. Key market trends, growth factors and opportunities
    • 6.5.2. Market size and forecast, by region
    • 6.5.3. Market share analysis by country

CHAPTER 7: GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION

  • 7.1. Overview
    • 7.1.1. Market size and forecast
  • 7.2. Oral
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by region
    • 7.2.3. Market share analysis by country
  • 7.3. Injectable
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by region
    • 7.3.3. Market share analysis by country

CHAPTER 8: GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL

  • 8.1. Overview
    • 8.1.1. Market size and forecast
  • 8.2. Hospital Pharmacies
    • 8.2.1. Key market trends, growth factors and opportunities
    • 8.2.2. Market size and forecast, by region
    • 8.2.3. Market share analysis by country
  • 8.3. Specialty and Retail Pharmacies
    • 8.3.1. Key market trends, growth factors and opportunities
    • 8.3.2. Market size and forecast, by region
    • 8.3.3. Market share analysis by country
  • 8.4. Others
    • 8.4.1. Key market trends, growth factors and opportunities
    • 8.4.2. Market size and forecast, by region
    • 8.4.3. Market share analysis by country

CHAPTER 9: GASTRIC CANCER MARKET, BY REGION

  • 9.1. Overview
    • 9.1.1. Market size and forecast By Region
  • 9.2. North America
    • 9.2.1. Key trends and opportunities
    • 9.2.2. Market size and forecast, by Disease Type
    • 9.2.3. Market size and forecast, by Treatment Type
    • 9.2.4. Market size and forecast, by Drug Class Outlook
    • 9.2.5. Market size and forecast, by Route of Administration
    • 9.2.6. Market size and forecast, by Distribution Channel
    • 9.2.7. Market size and forecast, by country
      • 9.2.7.1. U.S.
      • 9.2.7.1.1. Key market trends, growth factors and opportunities
      • 9.2.7.1.2. Market size and forecast, by Disease Type
      • 9.2.7.1.3. Market size and forecast, by Treatment Type
      • 9.2.7.1.4. Market size and forecast, by Drug Class Outlook
      • 9.2.7.1.5. Market size and forecast, by Route of Administration
      • 9.2.7.1.6. Market size and forecast, by Distribution Channel
      • 9.2.7.2. Canada
      • 9.2.7.2.1. Key market trends, growth factors and opportunities
      • 9.2.7.2.2. Market size and forecast, by Disease Type
      • 9.2.7.2.3. Market size and forecast, by Treatment Type
      • 9.2.7.2.4. Market size and forecast, by Drug Class Outlook
      • 9.2.7.2.5. Market size and forecast, by Route of Administration
      • 9.2.7.2.6. Market size and forecast, by Distribution Channel
      • 9.2.7.3. Mexico
      • 9.2.7.3.1. Key market trends, growth factors and opportunities
      • 9.2.7.3.2. Market size and forecast, by Disease Type
      • 9.2.7.3.3. Market size and forecast, by Treatment Type
      • 9.2.7.3.4. Market size and forecast, by Drug Class Outlook
      • 9.2.7.3.5. Market size and forecast, by Route of Administration
      • 9.2.7.3.6. Market size and forecast, by Distribution Channel
  • 9.3. Europe
    • 9.3.1. Key trends and opportunities
    • 9.3.2. Market size and forecast, by Disease Type
    • 9.3.3. Market size and forecast, by Treatment Type
    • 9.3.4. Market size and forecast, by Drug Class Outlook
    • 9.3.5. Market size and forecast, by Route of Administration
    • 9.3.6. Market size and forecast, by Distribution Channel
    • 9.3.7. Market size and forecast, by country
      • 9.3.7.1. Germany
      • 9.3.7.1.1. Key market trends, growth factors and opportunities
      • 9.3.7.1.2. Market size and forecast, by Disease Type
      • 9.3.7.1.3. Market size and forecast, by Treatment Type
      • 9.3.7.1.4. Market size and forecast, by Drug Class Outlook
      • 9.3.7.1.5. Market size and forecast, by Route of Administration
      • 9.3.7.1.6. Market size and forecast, by Distribution Channel
      • 9.3.7.2. UK
      • 9.3.7.2.1. Key market trends, growth factors and opportunities
      • 9.3.7.2.2. Market size and forecast, by Disease Type
      • 9.3.7.2.3. Market size and forecast, by Treatment Type
      • 9.3.7.2.4. Market size and forecast, by Drug Class Outlook
      • 9.3.7.2.5. Market size and forecast, by Route of Administration
      • 9.3.7.2.6. Market size and forecast, by Distribution Channel
      • 9.3.7.3. France
      • 9.3.7.3.1. Key market trends, growth factors and opportunities
      • 9.3.7.3.2. Market size and forecast, by Disease Type
      • 9.3.7.3.3. Market size and forecast, by Treatment Type
      • 9.3.7.3.4. Market size and forecast, by Drug Class Outlook
      • 9.3.7.3.5. Market size and forecast, by Route of Administration
      • 9.3.7.3.6. Market size and forecast, by Distribution Channel
      • 9.3.7.4. Spain
      • 9.3.7.4.1. Key market trends, growth factors and opportunities
      • 9.3.7.4.2. Market size and forecast, by Disease Type
      • 9.3.7.4.3. Market size and forecast, by Treatment Type
      • 9.3.7.4.4. Market size and forecast, by Drug Class Outlook
      • 9.3.7.4.5. Market size and forecast, by Route of Administration
      • 9.3.7.4.6. Market size and forecast, by Distribution Channel
      • 9.3.7.5. Italy
      • 9.3.7.5.1. Key market trends, growth factors and opportunities
      • 9.3.7.5.2. Market size and forecast, by Disease Type
      • 9.3.7.5.3. Market size and forecast, by Treatment Type
      • 9.3.7.5.4. Market size and forecast, by Drug Class Outlook
      • 9.3.7.5.5. Market size and forecast, by Route of Administration
      • 9.3.7.5.6. Market size and forecast, by Distribution Channel
      • 9.3.7.6. Rest of Europe
      • 9.3.7.6.1. Key market trends, growth factors and opportunities
      • 9.3.7.6.2. Market size and forecast, by Disease Type
      • 9.3.7.6.3. Market size and forecast, by Treatment Type
      • 9.3.7.6.4. Market size and forecast, by Drug Class Outlook
      • 9.3.7.6.5. Market size and forecast, by Route of Administration
      • 9.3.7.6.6. Market size and forecast, by Distribution Channel
  • 9.4. Asia-Pacific
    • 9.4.1. Key trends and opportunities
    • 9.4.2. Market size and forecast, by Disease Type
    • 9.4.3. Market size and forecast, by Treatment Type
    • 9.4.4. Market size and forecast, by Drug Class Outlook
    • 9.4.5. Market size and forecast, by Route of Administration
    • 9.4.6. Market size and forecast, by Distribution Channel
    • 9.4.7. Market size and forecast, by country
      • 9.4.7.1. China
      • 9.4.7.1.1. Key market trends, growth factors and opportunities
      • 9.4.7.1.2. Market size and forecast, by Disease Type
      • 9.4.7.1.3. Market size and forecast, by Treatment Type
      • 9.4.7.1.4. Market size and forecast, by Drug Class Outlook
      • 9.4.7.1.5. Market size and forecast, by Route of Administration
      • 9.4.7.1.6. Market size and forecast, by Distribution Channel
      • 9.4.7.2. Japan
      • 9.4.7.2.1. Key market trends, growth factors and opportunities
      • 9.4.7.2.2. Market size and forecast, by Disease Type
      • 9.4.7.2.3. Market size and forecast, by Treatment Type
      • 9.4.7.2.4. Market size and forecast, by Drug Class Outlook
      • 9.4.7.2.5. Market size and forecast, by Route of Administration
      • 9.4.7.2.6. Market size and forecast, by Distribution Channel
      • 9.4.7.3. India
      • 9.4.7.3.1. Key market trends, growth factors and opportunities
      • 9.4.7.3.2. Market size and forecast, by Disease Type
      • 9.4.7.3.3. Market size and forecast, by Treatment Type
      • 9.4.7.3.4. Market size and forecast, by Drug Class Outlook
      • 9.4.7.3.5. Market size and forecast, by Route of Administration
      • 9.4.7.3.6. Market size and forecast, by Distribution Channel
      • 9.4.7.4. South Korea
      • 9.4.7.4.1. Key market trends, growth factors and opportunities
      • 9.4.7.4.2. Market size and forecast, by Disease Type
      • 9.4.7.4.3. Market size and forecast, by Treatment Type
      • 9.4.7.4.4. Market size and forecast, by Drug Class Outlook
      • 9.4.7.4.5. Market size and forecast, by Route of Administration
      • 9.4.7.4.6. Market size and forecast, by Distribution Channel
      • 9.4.7.5. Australia
      • 9.4.7.5.1. Key market trends, growth factors and opportunities
      • 9.4.7.5.2. Market size and forecast, by Disease Type
      • 9.4.7.5.3. Market size and forecast, by Treatment Type
      • 9.4.7.5.4. Market size and forecast, by Drug Class Outlook
      • 9.4.7.5.5. Market size and forecast, by Route of Administration
      • 9.4.7.5.6. Market size and forecast, by Distribution Channel
      • 9.4.7.6. Rest of Asia-Pacific
      • 9.4.7.6.1. Key market trends, growth factors and opportunities
      • 9.4.7.6.2. Market size and forecast, by Disease Type
      • 9.4.7.6.3. Market size and forecast, by Treatment Type
      • 9.4.7.6.4. Market size and forecast, by Drug Class Outlook
      • 9.4.7.6.5. Market size and forecast, by Route of Administration
      • 9.4.7.6.6. Market size and forecast, by Distribution Channel
  • 9.5. LAMEA
    • 9.5.1. Key trends and opportunities
    • 9.5.2. Market size and forecast, by Disease Type
    • 9.5.3. Market size and forecast, by Treatment Type
    • 9.5.4. Market size and forecast, by Drug Class Outlook
    • 9.5.5. Market size and forecast, by Route of Administration
    • 9.5.6. Market size and forecast, by Distribution Channel
    • 9.5.7. Market size and forecast, by country
      • 9.5.7.1. Brazil
      • 9.5.7.1.1. Key market trends, growth factors and opportunities
      • 9.5.7.1.2. Market size and forecast, by Disease Type
      • 9.5.7.1.3. Market size and forecast, by Treatment Type
      • 9.5.7.1.4. Market size and forecast, by Drug Class Outlook
      • 9.5.7.1.5. Market size and forecast, by Route of Administration
      • 9.5.7.1.6. Market size and forecast, by Distribution Channel
      • 9.5.7.2. United Arab Emirates
      • 9.5.7.2.1. Key market trends, growth factors and opportunities
      • 9.5.7.2.2. Market size and forecast, by Disease Type
      • 9.5.7.2.3. Market size and forecast, by Treatment Type
      • 9.5.7.2.4. Market size and forecast, by Drug Class Outlook
      • 9.5.7.2.5. Market size and forecast, by Route of Administration
      • 9.5.7.2.6. Market size and forecast, by Distribution Channel
      • 9.5.7.3. Saudi Arabia
      • 9.5.7.3.1. Key market trends, growth factors and opportunities
      • 9.5.7.3.2. Market size and forecast, by Disease Type
      • 9.5.7.3.3. Market size and forecast, by Treatment Type
      • 9.5.7.3.4. Market size and forecast, by Drug Class Outlook
      • 9.5.7.3.5. Market size and forecast, by Route of Administration
      • 9.5.7.3.6. Market size and forecast, by Distribution Channel
      • 9.5.7.4. South Africa
      • 9.5.7.4.1. Key market trends, growth factors and opportunities
      • 9.5.7.4.2. Market size and forecast, by Disease Type
      • 9.5.7.4.3. Market size and forecast, by Treatment Type
      • 9.5.7.4.4. Market size and forecast, by Drug Class Outlook
      • 9.5.7.4.5. Market size and forecast, by Route of Administration
      • 9.5.7.4.6. Market size and forecast, by Distribution Channel
      • 9.5.7.5. Rest of LAMEA
      • 9.5.7.5.1. Key market trends, growth factors and opportunities
      • 9.5.7.5.2. Market size and forecast, by Disease Type
      • 9.5.7.5.3. Market size and forecast, by Treatment Type
      • 9.5.7.5.4. Market size and forecast, by Drug Class Outlook
      • 9.5.7.5.5. Market size and forecast, by Route of Administration
      • 9.5.7.5.6. Market size and forecast, by Distribution Channel

CHAPTER 10: COMPETITIVE LANDSCAPE

  • 10.1. Introduction
  • 10.2. Top winning strategies
  • 10.3. Product Mapping of Top 10 Player
  • 10.4. Competitive Dashboard
  • 10.5. Competitive Heatmap
  • 10.6. Top player positioning, 2021

CHAPTER 11: COMPANY PROFILES

  • 11.1. Novartis AG
    • 11.1.1. Company overview
    • 11.1.2. Key Executives
    • 11.1.3. Company snapshot
  • 11.2. Pfizer, Inc.
    • 11.2.1. Company overview
    • 11.2.2. Key Executives
    • 11.2.3. Company snapshot
  • 11.3. Mylan N.V.
    • 11.3.1. Company overview
    • 11.3.2. Key Executives
    • 11.3.3. Company snapshot
  • 11.4. F. Hoffmann La Roche Ltd.
    • 11.4.1. Company overview
    • 11.4.2. Key Executives
    • 11.4.3. Company snapshot
  • 11.5. Eli Lilly And Company
    • 11.5.1. Company overview
    • 11.5.2. Key Executives
    • 11.5.3. Company snapshot
  • 11.6. Merck & Co., Inc.
    • 11.6.1. Company overview
    • 11.6.2. Key Executives
    • 11.6.3. Company snapshot
  • 11.7. Teva Pharmaceutical Industries Ltd.
    • 11.7.1. Company overview
    • 11.7.2. Key Executives
    • 11.7.3. Company snapshot
  • 11.8. Celltrion Healthcare Co., Ltd.
    • 11.8.1. Company overview
    • 11.8.2. Key Executives
    • 11.8.3. Company snapshot
  • 11.9. samsung bioepis
    • 11.9.1. Company overview
    • 11.9.2. Key Executives
    • 11.9.3. Company snapshot
  • 11.10. Bristol Myers Squibb Company
    • 11.10.1. Company overview
    • 11.10.2. Key Executives
    • 11.10.3. Company snapshot

LIST OF TABLES

  • TABLE 01. GLOBAL GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 02. GASTRIC CANCER MARKET FOR ADENOCARCINOMA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 03. GASTRIC CANCER MARKET FOR LYMPHOMA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 04. GASTRIC CANCER MARKET FOR GASTROINTESTINAL STROMAL TUMOR, BY REGION, 2021-2031 ($MILLION)
  • TABLE 05. GASTRIC CANCER MARKET FOR CARCINOID TUMOR, BY REGION, 2021-2031 ($MILLION)
  • TABLE 06. GASTRIC CANCER MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 07. GLOBAL GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 08. GASTRIC CANCER MARKET FOR IMMUNOTHERAPY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 09. GASTRIC CANCER MARKET FOR TARGETED THERAPY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 10. GASTRIC CANCER MARKET FOR CHEMOTHERAPY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 11. GASTRIC CANCER MARKET FOR RADIATION THERAPY AND SURGERY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 12. GLOBAL GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 13. GASTRIC CANCER MARKET FOR PD-1/PD-L1 INHIBITORS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 14. GASTRIC CANCER MARKET FOR HER2 ANTAGONISTS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 15. GASTRIC CANCER MARKET FOR VEGFR2 ANTAGONISTS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 16. GASTRIC CANCER MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 17. GLOBAL GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 18. GASTRIC CANCER MARKET FOR ORAL, BY REGION, 2021-2031 ($MILLION)
  • TABLE 19. GASTRIC CANCER MARKET FOR INJECTABLE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 20. GLOBAL GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 21. GASTRIC CANCER MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 22. GASTRIC CANCER MARKET FOR SPECIALTY AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 23. GASTRIC CANCER MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 24. GASTRIC CANCER MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 25. NORTH AMERICA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 26. NORTH AMERICA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 27. NORTH AMERICA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 28. NORTH AMERICA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 29. NORTH AMERICA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 30. NORTH AMERICA GASTRIC CANCER MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 31. U.S. GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 32. U.S. GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 33. U.S. GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 34. U.S. GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 35. U.S. GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 36. CANADA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 37. CANADA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 38. CANADA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 39. CANADA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 40. CANADA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 41. MEXICO GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 42. MEXICO GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 43. MEXICO GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 44. MEXICO GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 45. MEXICO GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 46. EUROPE GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 47. EUROPE GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 48. EUROPE GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 49. EUROPE GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 50. EUROPE GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 51. EUROPE GASTRIC CANCER MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 52. GERMANY GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 53. GERMANY GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 54. GERMANY GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 55. GERMANY GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 56. GERMANY GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 57. UK GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 58. UK GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 59. UK GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 60. UK GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 61. UK GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 62. FRANCE GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 63. FRANCE GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 64. FRANCE GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 65. FRANCE GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 66. FRANCE GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 67. SPAIN GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 68. SPAIN GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 69. SPAIN GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 70. SPAIN GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 71. SPAIN GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 72. ITALY GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 73. ITALY GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 74. ITALY GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 75. ITALY GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 76. ITALY GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 77. REST OF EUROPE GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 78. REST OF EUROPE GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 79. REST OF EUROPE GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 80. REST OF EUROPE GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 81. REST OF EUROPE GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 82. ASIA-PACIFIC GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 83. ASIA-PACIFIC GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 84. ASIA-PACIFIC GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 85. ASIA-PACIFIC GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 86. ASIA-PACIFIC GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 87. ASIA-PACIFIC GASTRIC CANCER MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 88. CHINA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 89. CHINA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 90. CHINA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 91. CHINA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 92. CHINA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 93. JAPAN GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 94. JAPAN GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 95. JAPAN GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 96. JAPAN GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 97. JAPAN GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 98. INDIA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 99. INDIA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 100. INDIA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 101. INDIA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 102. INDIA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 103. SOUTH KOREA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 104. SOUTH KOREA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 105. SOUTH KOREA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 106. SOUTH KOREA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 107. SOUTH KOREA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 108. AUSTRALIA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 109. AUSTRALIA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 110. AUSTRALIA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 111. AUSTRALIA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 112. AUSTRALIA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 113. REST OF ASIA-PACIFIC GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 114. REST OF ASIA-PACIFIC GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 115. REST OF ASIA-PACIFIC GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 116. REST OF ASIA-PACIFIC GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 117. REST OF ASIA-PACIFIC GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 118. LAMEA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 119. LAMEA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 120. LAMEA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 121. LAMEA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 122. LAMEA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 123. LAMEA GASTRIC CANCER MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 124. BRAZIL GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 125. BRAZIL GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 126. BRAZIL GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 127. BRAZIL GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 128. BRAZIL GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 129. UNITED ARAB EMIRATES GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 130. UNITED ARAB EMIRATES GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 131. UNITED ARAB EMIRATES GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 132. UNITED ARAB EMIRATES GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 133. UNITED ARAB EMIRATES GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 134. SAUDI ARABIA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 135. SAUDI ARABIA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 136. SAUDI ARABIA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 137. SAUDI ARABIA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 138. SAUDI ARABIA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 139. SOUTH AFRICA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 140. SOUTH AFRICA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 141. SOUTH AFRICA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 142. SOUTH AFRICA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 143. SOUTH AFRICA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 144. REST OF LAMEA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 145. REST OF LAMEA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 146. REST OF LAMEA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 147. REST OF LAMEA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 148. REST OF LAMEA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 149. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 150. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 151. PFIZER, INC.: KEY EXECUTIVES
  • TABLE 152. PFIZER, INC.: COMPANY SNAPSHOT
  • TABLE 153. MYLAN N.V.: KEY EXECUTIVES
  • TABLE 154. MYLAN N.V.: COMPANY SNAPSHOT
  • TABLE 155. F. HOFFMANN LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 156. F. HOFFMANN LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 157. ELI LILLY AND COMPANY: KEY EXECUTIVES
  • TABLE 158. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 159. MERCK & CO., INC.: KEY EXECUTIVES
  • TABLE 160. MERCK & CO., INC.: COMPANY SNAPSHOT
  • TABLE 161. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 162. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 163. CELLTRION HEALTHCARE CO., LTD.: KEY EXECUTIVES
  • TABLE 164. CELLTRION HEALTHCARE CO., LTD.: COMPANY SNAPSHOT
  • TABLE 165. SAMSUNG BIOEPIS: KEY EXECUTIVES
  • TABLE 166. SAMSUNG BIOEPIS: COMPANY SNAPSHOT
  • TABLE 167. BRISTOL MYERS SQUIBB COMPANY: KEY EXECUTIVES
  • TABLE 168. BRISTOL MYERS SQUIBB COMPANY: COMPANY SNAPSHOT

LIST OF FIGURES

  • FIGURE 01. GASTRIC CANCER MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF GASTRIC CANCER MARKET, 2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN GASTRIC CANCER MARKET (2022-2031)
  • FIGURE 04. PORTER FIVE-1
  • FIGURE 05. PORTER FIVE-2
  • FIGURE 06. PORTER FIVE-3
  • FIGURE 07. PORTER FIVE-4
  • FIGURE 08. PORTER FIVE-5
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALGASTRIC CANCER MARKET
  • FIGURE 10. IMPACT OF KEY REGULATION: GASTRIC CANCER MARKET
  • FIGURE 11. MARKET SHARE ANALYSIS: GASTRIC CANCER MARKET
  • FIGURE 12. PATENT ANALYSIS BY COMPANY
  • FIGURE 13. PATENT ANALYSIS BY COUNTRY
  • FIGURE 14. REGULATORY GUIDELINES: GASTRIC CANCER MARKET
  • FIGURE 15. VALUE CHAIN ANALYSIS: GASTRIC CANCER MARKET
  • FIGURE 16. GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER MARKET FOR ADENOCARCINOMA, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER MARKET FOR LYMPHOMA, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER MARKET FOR GASTROINTESTINAL STROMAL TUMOR, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER MARKET FOR CARCINOID TUMOR, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER MARKET FOR OTHERS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 22. GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER MARKET FOR IMMUNOTHERAPY, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 24. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER MARKET FOR TARGETED THERAPY, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 25. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER MARKET FOR CHEMOTHERAPY, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 26. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER MARKET FOR RADIATION THERAPY AND SURGERY, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 27. GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021(%)
  • FIGURE 28. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER MARKET FOR PD-1/PD-L1 INHIBITORS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 29. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER MARKET FOR HER2 ANTAGONISTS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 30. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER MARKET FOR VEGFR2 ANTAGONISTS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 31. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER MARKET FOR OTHERS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 32. GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021(%)
  • FIGURE 33. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER MARKET FOR ORAL, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 34. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER MARKET FOR INJECTABLE, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 35. GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
  • FIGURE 36. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 37. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER MARKET FOR SPECIALTY AND RETAIL PHARMACIES, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 38. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER MARKET FOR OTHERS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 39. GASTRIC CANCER MARKET BY REGION, 2021
  • FIGURE 40. U.S. GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 41. CANADA GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 42. MEXICO GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 43. GERMANY GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 44. UK GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 45. FRANCE GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 46. SPAIN GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 47. ITALY GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 48. REST OF EUROPE GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 49. CHINA GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 50. JAPAN GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 51. INDIA GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 52. SOUTH KOREA GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 53. AUSTRALIA GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 54. REST OF ASIA-PACIFIC GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 55. BRAZIL GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 56. UNITED ARAB EMIRATES GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 57. SAUDI ARABIA GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 58. SOUTH AFRICA GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 59. REST OF LAMEA GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 60. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 61. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 62. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 63. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 64. COMPETITIVE DASHBOARD
  • FIGURE 65. COMPETITIVE HEATMAP: GASTRIC CANCER MARKET
  • FIGURE 66. TOP PLAYER POSITIONING, 2021